Profiel
Scott D.
Kelley served as Vice President & Medical Director at Aspect Medical Systems, Inc. from 2000 to 2011.
Prior to that, he was an Associate Professor & Director-Liver Transplant at The University of California, San Francisco from 1990 to 2000.
He also served as Chief Medical Officer at Flexion Therapeutics, Inc. from 2017 to 2021.
In addition, he held a position as Vice President-Medical Affairs at Sanofi Corp.
Dr. Kelley received his undergraduate and graduate degrees from Stanford University and his doctorate from The University of California, San Francisco in 1984.
Eerdere bekende functies van Scott D. Kelley
| Bedrijven | Functie | Einde |
|---|---|---|
| FLEXION THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31-05-2021 |
| The University of California, San Francisco | Corporate Officer/Principal | 01-01-2000 |
| Sanofi Corp. | Corporate Officer/Principal | - |
Aspect Medical Systems, Inc.
 Aspect Medical Systems, Inc. Medical SpecialtiesHealth Technology Aspect Medical Systems, Inc. developed and manufactured anesthesia monitoring system that was called Bispectral (BIS) system. The company was founded in 1987 and was headquartered in Norwood, MA. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Scott D. Kelley
| Stanford University | Graduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Aspect Medical Systems, Inc.
Aspect Medical Systems, Inc. Medical SpecialtiesHealth Technology Aspect Medical Systems, Inc. developed and manufactured anesthesia monitoring system that was called Bispectral (BIS) system. The company was founded in 1987 and was headquartered in Norwood, MA. | Health Technology |
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
| Sanofi Corp. |
